ReviewNoro psikiyatri arsivi2018
Multiple Sclerosis Functional Composite.
Review in Noro psikiyatri arsivi, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Trial
- Use of clinical outcome assessments in specialty drug coverage policies.Journal of managed care & specialty pharmacy · 2026Article
- Outcome measures assisting treatment optimization in multiple sclerosis.Journal of neurology · 2022Review
- Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients.Annals of clinical and translational neurology · 2021Article
- Effects of Physical Therapy and Dalfampridine on Function and Quality of Life in Nonambulatory Individuals With Multiple Sclerosis: A Randomized Controlled Trial.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional disorders due to multiple sclerosis are evaluated using rating scales. EDSS is a scant which is very inadequate in evaluating cognitive functions, is significantly limited in evaluating upper extremity functions and is highly difficult to repeat. Multiple Sclerosis Functional Composite (MSFC) is considered as a test that has been proposed in recent years in MS clinical trials and can overcome these negative features of EDSS. Three primary assessment methods were suggested for MSFC (9): 1) 25-step walking, 2) 9-Hole Peg test (9-HPT), and 3) Paced Auditory Serial Addition Test-3 (PASAT-3).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.